Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board

Galectin Therapeutics ( (GALT) ) has provided an announcement.

On March 12, 2026, Galectin Therapeutics appointed internationally recognized neurosurgeon-scientist Dr. Henry Brem to its Board of Directors as an independent director, with the move announced publicly on March 17, 2026. Brem, a long-time Johns Hopkins neurosurgery leader and co-director of its brain cancer program, is credited with transforming neurosurgical oncology through innovations such as image-guided surgery and the Gliadel wafer for brain tumors.

The company said Brem’s extensive experience in translational medicine, complex clinical development, and navigating regulatory approvals is expected to support Galectin’s strategic priorities as it advances belapectin for patients with MASH cirrhosis and portal hypertension. His appointment continues a push to deepen scientific and clinical expertise on the board, signaling a stronger governance and development framework as Galectin pursues late-stage programs in liver disease and cancer.

The most recent analyst rating on (GALT) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.

Spark’s Take on GALT Stock

According to Spark, TipRanks’ AI Analyst, GALT is a Neutral.

The score is held down primarily by weak financial performance (no meaningful revenue, sizable losses, negative equity, and ongoing cash burn with rising debt). Technicals also remain bearish with the stock below major moving averages and negative MACD, despite near-oversold readings. Offsetting these risks, corporate updates around NAVIGATE results, FDA interactions, and insider funding are constructive but not enough to outweigh the current financial and technical headwinds.

To see Spark’s full report on GALT stock, click here.

More about Galectin Therapeutics

Galectin Therapeutics Inc. is a biopharmaceutical company focused on developing galectin-3-targeted therapeutics for chronic liver disease and cancer. Its lead candidate, belapectin, a carbohydrate-based galectin-3 inhibitor with U.S. FDA Fast Track designation, is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis, as well as in combination immunotherapies for advanced head and neck cancers and other malignancies.

The company targets severe liver cirrhosis, a major unmet medical need and significant drug development opportunity, while seeking partners to advance additional oncology programs. Galectin leverages internal scientific expertise and external collaborations to pursue cost-effective clinical development and expand its presence in the high-need markets of fibrotic, inflammatory, and malignant diseases.

Average Trading Volume: 449,170

Technical Sentiment Signal: Hold

Current Market Cap: $205M

See more insights into GALT stock on TipRanks’ Stock Analysis page.